tirzepatide lawsuit Ozempic maker Novo Nordisk sues US rival over 'materially misleading' ads | Pharmaceuticals industry Novo Nordisk filed a lawsuit

Semaglutide is generally suitable for individuals who are overweight or obese (with a BMI of 30 or higher), or those with a BMI of 27 or higher and associated health conditions such as type 2 diabetes

GI-Driven Dehydration Compounds Sun and Heat Risk Gastrointestinal side effects are common with Wegovy, with nausea affecting up to 44% of patients in clinical trials, vomiting in 24%, and diarrhea in 30%

The theory now strongly supported by early data is that this triple action not only helps people eat less, but also encourages the body to burn off stored fat more aggressively

The right comparison starts with the research question, not the number of compounds